{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-24-000022","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.320838+00:00","generated_at":"2026-05-30T00:50:59.106530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS Q3 net loss narrows to $7.1M; Phase 3 AML interim analysis on track for Q4 2024","bullets":["Q3 net loss $7.1M ($0.10/sh) vs $9.3M ($0.33/sh) in Q3 2023; cash $21M.","Phase 3 REGAL (GPS) in AML: interim analysis of 60 events on track for Q4 2024.","FDA granted Rare Pediatric Disease Designation (RPDD) to GPS for pediatric AML.","SLS009 Phase 2a data in r/r AML to be presented at ASH Dec 8; 31% overall response.","R&D expenses $4.4M (-24% YoY); G&A expenses $3.0M (-14% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-24-000022","json":"https://secwatch.observer/filing/0001390478-24-000022.json","markdown":"https://secwatch.observer/filing/0001390478-24-000022.md","text":"https://secwatch.observer/filing/0001390478-24-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/0001390478-24-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:50:59.106530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}